# Treatment of Alzheimer's Disease With CX516 (Ampalex)

> **NCT00001662** · PHASE2 · COMPLETED · sponsor: **National Institute of Neurological Disorders and Stroke (NINDS)** · enrollment: 40 (—)

## Conditions studied

- Alzheimer's Disease
- Dementia

## Interventions

- **DRUG:** CX516 (Ampalex)

## Key facts

- **NCT ID:** NCT00001662
- **Lead sponsor:** National Institute of Neurological Disorders and Stroke (NINDS)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-12
- **Primary completion:** —
- **Final completion:** 2005-11
- **Target enrollment:** 40 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001662, "Treatment of Alzheimer's Disease With CX516 (Ampalex)". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00001662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*